Tools / Inside Trading Tracker
Inside Trading Tracker
Track insider trading activity at publicly traded companies to understand how executives are trading their shares.
Pfizer Inc. (PFE) Insider Trading Activity
Healthcare • Drug Manufacturers - General • 88,000 employees
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. It also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Litfulo, Velsipity, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, Somavert, Ngenla, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Inlyta, Bosulif, Mektovi, Padcev, Adcetris, Talzenna, Tukysa, Elrexfio, Tivdak, Lorbrena, and Braftovi brands. In addition, the company involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE, as well as has strategic clinical collaboration with Acepodia Inc. for the development of antibody-cell conjugation-based cell therapies in autoimmune diseases. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
Total Value
$8,364,610.75
Total Shares
81,801
Average Trade Value
$160,857.90
Most Active Insider
Bourla Albert
Total Activity: $45,922,352
Largest Single Transaction
$18,248,188
by Bourla Albert on Feb 27, 2025
30-Day Activity
0 Transactions
Volume: 0 shares
Value: $0
Name
|
Position
|
Date
|
Shares
|
Value
|
Holdings
|
Type
|
---|---|---|---|---|---|---|
Executive Vice President
Officer
|
Feb 27, 2025 | 48,419 | $1,515,999 | 122,413 (+39.6%) | Exercise/Conversion | |
Executive Vice President
Officer
|
Feb 27, 2025 | 1,683 | $43,926 | 109,851 (-1.5%) | Payment of Exercise Price | |
Executive Vice President
Officer
|
Feb 27, 2025 | 468 | $12,215 | 43,774 (-1.1%) | Payment of Exercise Price | |
Executive Vice President
Officer
|
Feb 27, 2025 | 17,846 | $465,067 | 25,928 (-68.8%) | Payment of Exercise Price | |
Executive Vice President
Officer
|
Feb 27, 2025 | 19,054 | $596,581 | 44,242 (+43.1%) | Exercise/Conversion | |
Executive Vice President
Officer
|
Feb 27, 2025 | 45,347 | $1,181,743 | 75,958 (-59.7%) | Payment of Exercise Price | |
Executive Vice President
Officer
|
Feb 27, 2025 | 1,108 | $28,919 | 121,305 (-0.9%) | Payment of Exercise Price | |
President, Rd
Officer
|
Feb 27, 2025 | 17,450 | $10,000 | 172,147 (+10.1%) | Grant | |
President, Rd
Officer
|
Feb 27, 2025 | 8,909 | $232,525 | 163,238 (-5.5%) | Payment of Exercise Price | |
Executive Vice President
Officer
|
Feb 27, 2025 | 2,178 | $56,846 | 248,688 (-0.9%) | Payment of Exercise Price | |
Executive Vice President
Officer
|
Feb 27, 2025 | 79,779 | $2,079,041 | 168,909 (-47.2%) | Payment of Exercise Price | |
Executive Vice President
Officer
|
Feb 27, 2025 | 85,182 | $2,667,048 | 250,866 (+34.0%) | Exercise/Conversion | |
Chairman CEO
Director, Officer
|
Feb 27, 2025 | 582,823 | $18,248,188 | 931,744 (+62.6%) | Exercise/Conversion | |
SVP Controller
Officer
|
Feb 27, 2025 | 553 | $14,433 | 30,510 (-1.8%) | Payment of Exercise Price | |
Chairman CEO
Director, Officer
|
Feb 27, 2025 | 18,300 | $477,630 | 913,444 (-2.0%) | Payment of Exercise Price | |
Chairman CEO
Director, Officer
|
Feb 27, 2025 | 545,855 | $14,224,981 | 367,589 (-148.5%) | Payment of Exercise Price | |
Executive Vice President
Officer
|
Feb 27, 2025 | 146,961 | $3,829,804 | 159,240 (-92.3%) | Payment of Exercise Price | |
SVP Controller
Officer
|
Feb 27, 2025 | 22,416 | $701,845 | 31,063 (+72.2%) | Exercise/Conversion | |
Executive Vice President
Officer
|
Feb 27, 2025 | 156,914 | $4,912,977 | 309,790 (+50.7%) | Exercise/Conversion | |
SVP Controller
Officer
|
Feb 27, 2025 | 20,994 | $547,104 | 9,516 (-220.6%) | Payment of Exercise Price | |
Executive Vice President
Officer
|
Feb 27, 2025 | 3,589 | $93,673 | 306,201 (-1.2%) | Payment of Exercise Price | |
Executive Vice President
Officer
|
Feb 27, 2025 | 68,022 | $1,772,653 | 41,829 (-162.6%) | Payment of Exercise Price | |
Executive Vice President
Officer
|
Feb 27, 2025 | 72,629 | $2,274,014 | 111,534 (+65.1%) | Exercise/Conversion | |
President, Rd
Officer
|
Feb 26, 2025 | 9,687 | $10,000 | 159,972 (+6.1%) | Grant | |
Executive Vice President
Officer
|
Feb 26, 2025 | 3,220 | $85,072 | 73,994 (-4.4%) | Payment of Exercise Price | |
President, Rd
Officer
|
Feb 26, 2025 | 4,872 | $128,718 | 155,100 (-3.1%) | Payment of Exercise Price | |
SVP Controller
Officer
|
Feb 23, 2025 | 390 | $10,257 | 9,024 (-4.3%) | Payment of Exercise Price | |
President, Rd
Officer
|
Feb 23, 2025 | 662 | $17,411 | 150,285 (-0.4%) | Payment of Exercise Price | |
Executive Vice President
Officer
|
Feb 22, 2025 | 11,343 | $295,825 | 25,188 (-45.0%) | Payment of Exercise Price | |
SVP Controller
Officer
|
Feb 22, 2025 | 8,741 | $263,716 | 17,602 (+49.7%) | Exercise/Conversion | |
SVP Controller
Officer
|
Feb 22, 2025 | 390 | $10,257 | 17,212 (-2.3%) | Payment of Exercise Price | |
Executive Vice President
Officer
|
Feb 22, 2025 | 497 | $13,071 | 87,139 (-0.6%) | Payment of Exercise Price | |
SVP Controller
Officer
|
Feb 22, 2025 | 7,798 | $203,372 | 9,414 (-82.8%) | Payment of Exercise Price | |
Executive Vice President
Officer
|
Feb 22, 2025 | 11,125 | $335,641 | 87,636 (+12.7%) | Exercise/Conversion | |
Executive Vice President
Officer
|
Feb 22, 2025 | 9,925 | $258,844 | 77,214 (-12.9%) | Payment of Exercise Price | |
Executive Vice President
Officer
|
Feb 22, 2025 | 63,573 | $1,917,997 | 225,184 (+28.2%) | Exercise/Conversion | |
Executive Vice President
Officer
|
Feb 22, 2025 | 2,785 | $73,246 | 222,399 (-1.3%) | Payment of Exercise Price | |
Executive Vice President
Officer
|
Feb 22, 2025 | 56,715 | $1,479,127 | 165,684 (-34.2%) | Payment of Exercise Price | |
Executive Vice President
Officer
|
Feb 22, 2025 | 85,824 | $2,589,310 | 232,775 (+36.9%) | Exercise/Conversion | |
Chairman CEO
Director, Officer
|
Feb 22, 2025 | 238,399 | $7,192,498 | 570,436 (+41.8%) | Exercise/Conversion | |
Executive Vice President
Officer
|
Feb 22, 2025 | 3,334 | $87,684 | 229,441 (-1.5%) | Payment of Exercise Price | |
Executive Vice President
Officer
|
Feb 22, 2025 | 76,565 | $1,996,815 | 152,876 (-50.1%) | Payment of Exercise Price | |
Chairman CEO
Director, Officer
|
Feb 22, 2025 | 8,835 | $232,361 | 561,601 (-1.6%) | Payment of Exercise Price | |
Chairman CEO
Director, Officer
|
Feb 22, 2025 | 212,680 | $5,546,694 | 348,921 (-61.0%) | Payment of Exercise Price | |
President, Rd
Officer
|
Feb 22, 2025 | 7,798 | $203,372 | 150,947 (-5.2%) | Payment of Exercise Price | |
President, Rd
Officer
|
Feb 22, 2025 | 340 | $8,942 | 158,745 (-0.2%) | Payment of Exercise Price | |
President, Rd
Officer
|
Feb 22, 2025 | 8,741 | $263,716 | 159,085 (+5.5%) | Exercise/Conversion | |
Executive Vice President
Officer
|
Feb 22, 2025 | 12,714 | $383,581 | 37,099 (+34.3%) | Exercise/Conversion | |
Executive Vice President
Officer
|
Feb 22, 2025 | 568 | $14,938 | 36,531 (-1.6%) | Payment of Exercise Price | |
Director
|
Feb 13, 2025 | 19,457 | $499,072 | 27,707 (+70.2%) | Purchase | |
President, Rd
Officer
|
Jan 31, 2025 | 12,038 | $319,248 | 150,344 (-8.0%) | Payment of Exercise Price | |
Director
|
Oct 30, 2024 | 1,000 | $28,240 | 10,000 (+10.0%) | Purchase |